ZA200709780B - Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues - Google Patents

Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues

Info

Publication number
ZA200709780B
ZA200709780B ZA200709780A ZA200709780A ZA200709780B ZA 200709780 B ZA200709780 B ZA 200709780B ZA 200709780 A ZA200709780 A ZA 200709780A ZA 200709780 A ZA200709780 A ZA 200709780A ZA 200709780 B ZA200709780 B ZA 200709780B
Authority
ZA
South Africa
Prior art keywords
egfr
copy number
tumor tissues
antibody therapy
therapy based
Prior art date
Application number
ZA200709780A
Other languages
English (en)
Inventor
Siena Salvatore
Marrapese Giovanna
Veronese Silvio
Benvenuti Silvia
Bardelli Alberto
Moroni Mauro
Sartore-Bianchi Andrea
Gambacorta Marcello
Di Nicolantonio Federica
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200709780B publication Critical patent/ZA200709780B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA200709780A 2005-04-14 2007-11-13 Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues ZA200709780B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05008156 2005-04-14

Publications (1)

Publication Number Publication Date
ZA200709780B true ZA200709780B (en) 2008-11-26

Family

ID=36645327

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709780A ZA200709780B (en) 2005-04-14 2007-11-13 Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues

Country Status (12)

Country Link
US (1) US20090269344A1 (zh)
EP (1) EP1869208A1 (zh)
JP (1) JP2008535508A (zh)
KR (1) KR20080003422A (zh)
CN (1) CN101155932A (zh)
AU (1) AU2006233675A1 (zh)
BR (1) BRPI0610440A2 (zh)
CA (1) CA2604300A1 (zh)
MX (1) MX2007012570A (zh)
RU (1) RU2007141067A (zh)
WO (1) WO2006108627A1 (zh)
ZA (1) ZA200709780B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107854A2 (en) * 2005-04-01 2006-10-12 Amgen Inc. Epidermal growth factor receptor gene copy number
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CA2676049C (en) 2007-03-01 2018-04-10 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CA2680326A1 (en) 2007-03-13 2008-09-18 Amgen Inc. K-ras mutations and anti-egfr antibody therapy
WO2008112274A2 (en) * 2007-03-13 2008-09-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
RU2540146C2 (ru) 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
JP2013507987A (ja) * 2009-10-26 2013-03-07 アボット・ラボラトリーズ 非小細胞肺癌の予後を決定するための診断方法
US8609354B2 (en) * 2010-03-04 2013-12-17 Olli CARPEN Method for selecting patients for treatment with an EGFR inhibitor
AU2011222867B2 (en) 2010-03-04 2014-03-06 Annika Algars Method for selecting patients for treatment with an EGFR inhibitor
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
WO2012040387A1 (en) 2010-09-24 2012-03-29 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
DE102010060964A1 (de) * 2010-12-02 2012-06-06 Universitätsklinikum Hamburg-Eppendorf Verfahren zur Prädikation der therapeutischen Wirksamkeit von EGFR-Inhibitoren
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN102153648B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l4-h3及其编码基因与应用
MX2013011706A (es) 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
EP2802671B1 (en) * 2011-12-12 2018-07-18 Cellay, Inc. Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP4001311A1 (en) 2014-07-09 2022-05-25 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
JP6782698B2 (ja) * 2014-12-12 2020-11-11 セルキュイティー インコーポレイテッド がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
JP7080501B2 (ja) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物
EP3622522A1 (en) * 2017-12-01 2020-03-18 Illumina, Inc. Methods and systems for determining somatic mutation clonality
EP3591666A1 (en) * 2018-07-04 2020-01-08 Dassault Systèmes Simulating evolution of a tumor
CN112430646A (zh) * 2020-12-11 2021-03-02 南京求臻基因科技有限公司 一种基于数字pcr平台的egfr基因扩增的检测方法
CN112646893A (zh) * 2021-01-08 2021-04-13 北京泛生子基因科技有限公司 一种egfr基因拷贝数检测试剂盒及检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
WO2006107854A2 (en) * 2005-04-01 2006-10-12 Amgen Inc. Epidermal growth factor receptor gene copy number

Also Published As

Publication number Publication date
KR20080003422A (ko) 2008-01-07
CN101155932A (zh) 2008-04-02
RU2007141067A (ru) 2009-05-20
AU2006233675A1 (en) 2006-10-19
JP2008535508A (ja) 2008-09-04
WO2006108627A9 (en) 2007-10-11
MX2007012570A (es) 2007-11-16
EP1869208A1 (en) 2007-12-26
CA2604300A1 (en) 2006-10-19
WO2006108627A1 (en) 2006-10-19
US20090269344A1 (en) 2009-10-29
BRPI0610440A2 (pt) 2010-06-22

Similar Documents

Publication Publication Date Title
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
IL238045A0 (en) Tumor treatment with an antibody against vegf
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
WO2006102272A8 (en) Methods for treating tumors and cancerous tissues
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
IL190537A0 (en) Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof
EP1718145A4 (en) CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
IL179891A0 (en) Tumor specific antibody
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
HK1081448A1 (en) Bispecific anti-erb-b antibodies and their use in tumor therapy
EP1720575A4 (en) Therapeutic and diagnostic conjugates for use with multi-specific antibodies
IL188588A0 (en) Anti-ctla -4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
GB0519405D0 (en) Cancer therapy prognosis and target
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
AU2003224076A1 (en) Antibody combination useful for tumor therapy
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
EP1976554A4 (en) S-N-ACETYL SIALIC ACID ANTIGENS, ANTIBODIES THEREOF AND METHODS OF USE THEREOF IN ANTICANCER THERAPIES
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2010054377A3 (en) Fully human antibodies against n-cadherin
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
EP1934331A4 (en) PAX2 AS A TARGET FOR THE INDUCTION OF DEFB1-MEDIATED TUMORIMMUNITY AND CANCER THERAPY